Engraftment and GVHD
| . | Event . | P . |
|---|---|---|
| Median days to ANC >0.5 × 109/L (IQR) | ||
| Haplo | 18 (16-20) | .001 |
| Haplo-cord | 11 (10-14) | |
| Median days to platelet >20 × 109/L (IQR) | ||
| Haplo | 25 (20-32) | .025 |
| Haplo-cord | 22 (17-36) | |
| Cumulative incidence grade 2-4 acute GVHD, day 100 (95% CI) | ||
| Haplo | 33% (27-39) | .0001 |
| Haplo-cord | 16% (9-23) | |
| Cumulative incidence grade 3-4 acute GVHD, day 100 (95% CI) | ||
| Haplo | 9% (5-13) | .275 |
| Haplo-cord | 5% (1-9) | |
| Cumulative incidence chronic GVHD at 1 y (95% CI) | ||
| Haplo | 16% (12-20) | .0001 |
| Haplo-cord | 4% (0-10) |
| . | Event . | P . |
|---|---|---|
| Median days to ANC >0.5 × 109/L (IQR) | ||
| Haplo | 18 (16-20) | .001 |
| Haplo-cord | 11 (10-14) | |
| Median days to platelet >20 × 109/L (IQR) | ||
| Haplo | 25 (20-32) | .025 |
| Haplo-cord | 22 (17-36) | |
| Cumulative incidence grade 2-4 acute GVHD, day 100 (95% CI) | ||
| Haplo | 33% (27-39) | .0001 |
| Haplo-cord | 16% (9-23) | |
| Cumulative incidence grade 3-4 acute GVHD, day 100 (95% CI) | ||
| Haplo | 9% (5-13) | .275 |
| Haplo-cord | 5% (1-9) | |
| Cumulative incidence chronic GVHD at 1 y (95% CI) | ||
| Haplo | 16% (12-20) | .0001 |
| Haplo-cord | 4% (0-10) |
ANC, absolute neutrophil count.